Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
To investigate safety and feasibility of a tissue-regenerative approach to treat stress urinary incontinence (SUI) in female patients with a novel transurethral injection therapy using autologous MPCs in a combination with NMES.
Lead Product(s): Autologous Muscle Precursor Cell Therapy
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022